FDA Accepts Tinlarebant NDA with Priority Review; PDUFA Date Set for Feb 12, 2027

summarizeSummary

The FDA has accepted Belite Bio's NDA for tinlarebant in Stargardt Disease Type 1 with Priority Review, setting a PDUFA target action date of February 12, 2027. If approved, it would be the first-ever treatment for this rare, blinding disease.

check_boxKey Events · Product Development and Regulatory · BLTE

• FDA Accepts NDA with Priority Review

  The FDA accepted Belite Bio's New Drug Application for tinlarebant for Stargardt Disease Type 1 and granted Priority Review designation, accelerating the review timeline.

• PDUFA Date Set for February 12, 2027

  A clear catalyst for potential approval has emerged, with the FDA setting a target action date of February 12, 2027.

• First-Ever Treatment Potential

  If approved, tinlarebant would be the first FDA-approved therapy for STGD1, a disease affecting an estimated 53,000 people in the U.S. with no current treatment options.

• Phase 3 DRAGON Data Supports Filing

  The NDA is based on the Phase 3 DRAGON trial, which demonstrated a statistically significant 35.7% reduction in atrophic retinal lesion growth rate versus placebo.

auto_awesomeAnalysis · BLTE · Life Sciences

Acceptance of the tinlarebant NDA with Priority Review marks a pivotal regulatory milestone that substantially de-risks the path to potential approval. With a PDUFA date of February 12, 2027, the company now faces a defined timeline for a decision on what could become the first-ever treatment for Stargardt Disease Type 1—a rare inherited retinal disease that currently has no approved therapies. The Priority Review designation reflects the FDA's recognition of the high unmet medical need and the strength of the Phase 3 DRAGON data, which showed a 35.7% reduction in atrophic lesion growth. This event shifts the investment thesis from a clinical-stage narrative to a near-commercial opportunity, where approval could unlock a multi-billion dollar market.